Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

er Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements, and secondarily to a non-cash, non-operating expense of $1.3 million, which represents the increase in estimated fair value of the warrant liability.  

RevenueFor the quarter ended March 31, 2011, Palatin recognized $0.1 million of contract revenue under its license and collaboration agreement with AstraZeneca, compared to $2.6 million for the same period in 2010.

Costs and ExpensesTotal operating expenses for the quarter ended March 31, 2011 were $2.7 million compared to $4.6 million for the comparable quarter of 2010.  The net decrease in operating expenses for the quarter was primarily due to Palatin's previously disclosed realignment of resources and reduction in staffing levels in 2010.

Cash positionPalatin's cash and cash equivalents were $22.0 million as of March 31, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $1.9 million as of March 31, 2011 compared to $2.4 million as of June 30, 2010.  

The increase in cash and cash equivalents is attributable to Palatin's previously announced completion of its $23.0 million public offering in which Palatin sold 23,000,000 shares of its common stock, Series A warrants to purchase up to 2,000,000 shares of its common stock, and Series B warrants to purchase up to 21,000,000 shares of its common stock.  The net proceeds to Palatin, after deducting underwriting discounts and commissions and other offering expenses, were approximately $21.1 million.  

The Company believes, based on its current operating plan, that its cash and cash equivalents as of March 31, 2011 will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Pala
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... done and now they,ve done it. What,s more, they did ... U.S. Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... the first experimental demonstration of GRIN for gradient index ... a wide range of exotic optics, including superfast computers based ...
... 2011 Amgen (Nasdaq: AMGN ) and ... into a definitive acquisition agreement under which Amgen has ... venture-funded,  biotechnology company headquartered in Woburn, Mass. BioVex is ... Phase 3 clinical development, that may represent a new ...
... (Nasdaq: CEPH ) will hold a public memorial service ... and CEO on February 1, 2011, at 6:00 p.m. at The ... Dr. Baldino founded Cephalon in 1987 and led the ... ten biotechnology companies in the world. He was a recognized pioneer ...
Cached Biology Technology:GRIN plasmonics 2GRIN plasmonics 3GRIN plasmonics 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 2Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 3Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 5Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 6Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 7Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
(Date:4/23/2014)... 2014) A team of researchers in ... into the brains of nonhuman primates and assessed ... months found that the hNSCs had differentiated into ... tumors. , The study will be published in ... but is currently freely available on-line as an ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... One of the challenges of gene therapy - a ... (DNA or RNA) - is to assure that this material ... a substantial amount along the way and without producing any ... the use of different types of vectors, molecules capable of ...
... shellfish safer to eat has been pioneered by scientists at ... Institute for Agri-Food and Land Use, not only ensures shellfish ... but is likely to revolutionise the global fishing industry. While ... takes up to two days, the new test slashes the ...
... Aware, Inc. (Nasdaq: AWRE ), a leading ... industries, today announced that on January 5, 2011 its Board ... S. Stafford, III to the Aware Board of Directors.   ... Director and will serve on the Board,s Nominating and Corporate ...
Cached Biology News:Nanodisk gene therapy 2Shellfish safer to eat thanks to breakthrough by Queen's scientists 2Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3